Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 250

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 250
---

    ability to fund and complete our study and, if such study provides data supporting an FDA submission, our ability to apply for and
    obtain clearance from the FDA;

    ●
    our
    ability to remain a going concern;

    ●
    our
    ability to maintain our Nasdaq listing;

    ●
    our
    business strategy and plans;

    ●
    the
    potential market for our product candidate, if approved for sale in the U.S.;

    ●
    new
    regulatory pronouncements and changes in regulatory guidelines and timing of regulatory approvals;

    ●
    general
    and industry-specific economic conditions;

    ●
    variations
    in our quarterly financial and operating results, including the rate at which we incur negative cash flow in future periods;

    ●
    additions
    to or departures of our key personnel;

    ●
    changes
    in market valuations of other companies that operate in our business segments or in our industry;

    ●
    lack
    of trading liquidity;

    ●
    if
    our product is approved and becomes available for us to sell in the U.S., whether we ultimately achieve profitability or not;

    ●
    changes
    in accounting principles; and

    ●
    general
    market conditions, economic and other external factors.

The
market prices of the securities of early-stage companies, particularly companies like ours that are seeking to obtain regulatory approval
of their product candidate and do not yet generate operating revenue, have been highly volatile and are likely to remain highly volatile
in the future. This volatility has often been unrelated to the operating performance of particular companies. In the past, companies
that experience volatility in the market price of their securities have often faced securities class action litigation. Whether or not
meritorious, litigation brought against us could result in substantial costs, divert our management’s attention and resources and
harm our financial condition and results of operations.

51

Although
we have no preferred stock outstanding as of the date hereof and we have currently no intention to issue any preferred stock, our common
stockholders could be adversely affected by the issuance by us of preferred stock in the future, if any.

Our
certificate of incorporation does not restrict our ability to offer one or more series of preferred stock, any or all of which could
rank equally with or have preferences over our common stock as to dividend payments, voting rights, rights upon liquidation or other
types of rights. Our board